| CAS NO: | 306-07-0 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| Cas No. | 306-07-0 |
| 别名 | 优降宁盐酸盐；盐酸帕吉林；巴吉林盐酸盐 |
| 化学名 | N-methyl-N-2-propynyl-benzenemethanamine, monohydrochloride |
| Canonical SMILES | CN(CC#C)CC1=CC=CC=C1.Cl |
| 分子式 | C11H13N o HCl |
| 分子量 | 195.7 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 5mg/ml |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 11.52 nM: inhibits monoamine oxidase (MAO) type A (MAO-A). IC50: 8.2 nM: blocks MAO type B (MAO-B). Pargyline, an irreversible and non-selective inhibitor of MAO, is used to treat moderate hypertension and cancer cells. There are two isoforms of MAO, MAO-A and MAO-B. MAO-A preferentially deaminates melatonin, serotonin, norepinephrine and epinephrine. MAO-B catalyzes the oxidative deamination and inactivation of certain catecholamines within the presynaptic nerve terminals. In vitro: Pargyline reduced the proliferation of human prostate carcinoma (LNCaP-LN3) cells in a time- and dose-dependent fashion. In addition, compared to the control, pargyline remarkably triggered cell cycle arrest at the G1 phase. Pargyline elicited an increase in the cell death rate via promoting apoptosis, suggesting that pargyline was a powerful candidate drug for the treatment of human prostate cancer [1]. In vivo: Male rats were injected intraperitoneally pargyline at a dose of 75 mg/kg for 80 min. Pargyline significantly increased the concentration of extracellular dopamine in the striatum and simultaneously, significantly reduced the concentration of extracellular MAO-derived metabolite 3,4-dihydroxyphenylacetic acid to undetectable levels [2]. References: |
m.cnreagent.com